Asset
CAMIDANLUMAB TESIRINE
ADC Therapeutics SA Common Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02588092 | phase1 | terminated | 2016-02-01 | 2018-08-29 | ADC Therapeutics S.A. | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) |
| NCT03621982 | phase1 | terminated | 2018-11-09 | 2022-12-14 | ADC Therapeutics S.A. | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.